ADMA Biologics Raises FY24 Total Revenue Guidance To More Than $400M (Est $357.504M), FY25 Outlook To More Than $445M (Est $414.48M)
Portfolio Pulse from Benzinga Newsdesk
ADMA Biologics has raised its financial guidance for FY24 and FY25. The company now expects total revenue to exceed $400 million in FY24 and $445 million in FY25, up from previous estimates of $357.504 million and $414.48 million, respectively. Net income and Adjusted EBITDA projections have also been increased.
August 08, 2024 | 9:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics has significantly raised its financial guidance for FY24 and FY25, indicating strong future performance. The company now expects total revenue to exceed $400 million in FY24 and $445 million in FY25, with net income and Adjusted EBITDA also seeing substantial increases.
The upward revision in financial guidance for FY24 and FY25 suggests strong future performance for ADMA Biologics. This is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100